The U.S. glaucoma market has seen notable advances in the treatment of OAG following the launches of numerous innovative drugs over the past two years, including Bausch + Lomb’s Vyzulta and Aerie Pharmaceuticals’ Rhopressa and Rocklatan, as well as the highly anticipated launch of Allergan’s bimatoprost SR in 2020. In addition to new drugs, developments have occurred in the field of MIGS in recent years. However, market access decisions for these therapies in Medicare and commercial plans influence ophthalmologists’ prescribing decisions in OAG. Therefore, it is essential for drug marketers and developers to understand how U.S. payers and ophthalmologists react to new treatments entering the highly competitive OAG market.

QUESTIONS ANSWERED

  • Does coverage of therapies for OAG differ on MCOs’ largest Medicare and commercial insurance plans? How are payers covering newer-to-market OAG drugs and FDA-approved devices for MIGS on these plans?
  • What clinical and nonclinical factors contribute to a favorable formulary position for a branded OAG therapy?
  • How does the market access environment impact ophthalmologists’ prescribing of current therapies for OAG? What areas of drug development in OAG will be most compelling to payers and ophthalmologists?
  • How do payers intend to reimburse key emerging therapies bimatoprost SR and DE-117? How will the prescriber landscape evolve in OAG by 2022?

CONTENT HIGHLIGHTS

Geography: United States

Primary Research: Survey of 100 U.S. ophthalmologists, survey of 30 U.S. MCO PDs/MDs

Key Drugs Covered: Lumigan, Travatan Z, Combigan, Simbrinza, Alphagan P, Vyzulta, Rhopressa, Rocklatan, Xelpros, bimatoprost SR, DE-117, latanoprost, dorzolamide / timolol

Content highlights:

Reimbursement and contracting

Access and prescribing

Special topics

Opportunities and challenges for emerging therapies

PRODUCT DESCRIPTION

U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Access & Reimbursement Glaucoma US August 2019

Author(s): Himanshu Jain, M.S. Pharm

Himanshu is a Lead Analyst in the CNS/Ophthalmology team at Decision Resources Group, and has authored content for indications including age-related macular degeneration, diabetic retinopathy/diabetic macular edema, and unipolar depression. He comes with eight years of experience working on commercial assessment projects, including opportunity assessments, market intelligence, disease narratives, epi-based forecasts, patent research, and social media analysis, across multiple therapy areas. He holds a degree in Pharmacology from the National Institute of Pharmaceutical Education and Research (NIPER) in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.


Related Reports

Glaucoma | Current Treatment | Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

Drug treatment of glaucoma focuses on reducing / controlling IOP and preserving visual function. Given the availability of therapies from several drug cl...

View Details

Glaucoma | Epidemiology | Mature Markets Data

DRG Epidemiology’s coverage of glaucoma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,...

View Details